Close menu




May 21st, 2025 | 07:00 CEST

Stocks on the verge of MULTIPLYING? BioNTech, D-Wave, and hot stock Argo Living Soils aim to revolutionize their markets! Buy now?

  • Agriculture
  • Agribusiness
  • Technology
  • Biotechnology
  • computing
Photo credits: ChatGPT

These companies want to turn billion-dollar markets upside down: Argo Living Soils, BioNTech, and D-Wave. Argo Living Soils aims to revolutionize infrastructure construction through nanotechnology. Concrete and asphalt are to become more durable and environmentally friendly through nanotechnology. This could, for example, make buildings and bridges better protected against earthquakes. The potential is enormous, and the hot stock is valued at less than CAD 10 million, offering the chance for a multiple increase. D-Wave has impressively demonstrated how quickly a revaluation can take place. Quantum computing has the potential to change the world. But big players like Alphabet, NVIDIA, and others also want a big piece of the pie. At BioNTech, the focus remains on the fight against cancer. The stock appears to have halted its sell-off, but analysts are lowering their price targets. Where is the right entry point now?

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , D-WAVE QUANTUM INC | US26740W1099 , ARGO LIVING SOILS CORP | CA04018T3064

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Agro Living Soils aims to revolutionize the construction industry with nanotechnology

    Argo Living Soils aims to revolutionize infrastructure construction with nanotechnology. To this end, the Canadians are working on the next generation of concrete and asphalt. In the future, these materials will not only be more resource-efficient in production, but also more stable and durable. A few weeks ago, a cooperation with Graphene Leaders Canada was announced. Together, the partners want to work on adding graphene nanoplatelets (GNP) to concrete and asphalt.

    Like the more familiar graphite, the nanomaterial graphene is made from carbon. Due to its lightness and near transparency, it is often referred to as a "miracle material." Although only one atom thick, is over 100 times stronger than steel and electrically conductive. Graphene can also be combined with other materials such as plastic. This "miracle material" is already being used in computer chips, medical technology, and energy storage devices.

    Argo Living Soils now wants to bring graphene nanoplatelets (GNP) to the construction industry for stronger, more environmentally friendly infrastructure solutions. Incorporating graphene into concrete is expected to offer revolutionary advantages: It is expected to increase concrete's compressive and tensile strength by up to 30%, enabling structures with greater durability but less material. This could make buildings and bridges significantly more earthquake-resistant, for example. At the same time, the carbon footprint of concrete production, which causes high emissions, could be improved considerably. Using less cement should reduce CO2 emissions by up to 20%. In addition, the amount of water required for mixing concrete should be reduced. Similar advantages should be achieved when added to asphalt.

    If the development proves successful, the revenue potential would be enormous: While the global asphalt market has a volume of USD 82 billion, the concrete market is worth as much as USD 250 billion - with both markets continuing to grow. Given this potential, the current valuation of under CAD 10 million seems worth speculating on. The next press releases are likely to be exciting.

    D-Wave Quantum: Outshining supercomputers

    Agro Living Soils is heading in the same direction as D-Wave: industrial applications. In recent months, quantum computing has impressively demonstrated how quickly a topic of the future can become reality. Since November, D-Wave's share price has increased more than tenfold and is now worth almost USD 4 billion on the stock market. After sharp corrections in January and April, the USD 13 mark was broken in recent days and new all-time highs were reached. With expected annual revenue of just over USD 24 million, the valuation is certainly ambitious - but so is the potential. Many experts compare it to NVIDIA and the artificial intelligence of 10 years ago. However, a breakthrough in quantum computing could come even faster.

    Quantum computers promise to solve complex problems in areas such as optimization, cryptography, and simulations at speeds that will dwarf everything we know today. D-Wave is considered one of the pioneers of real-world applications. The Advantage2 system, based on quantum annealing technology, has now solved a simulation in just a few minutes that would have taken a classic supercomputer nearly 1 million years.

    In the first quarter of 2025, D-Wave Quantum's revenue exploded by 509% to USD 15 million. This means that analysts' estimates for the current year could also prove to be too low. On the other hand, more and more tech giants such as Alphabet, Microsoft, and NVIDIA are entering the market. So the race is only just beginning.

    BioNTech: Fighting cancer

    BioNTech aims to revolutionize the fight against cancer. The German biotech flagship has a full development pipeline and high cash reserves.

    When announcing the first quarter figures, CEO Prof. Dr. Ugur Sahin said: "In the first quarter of 2025, we continued to implement our strategic priorities consistently. This is demonstrated by data updates on our bispecific PD-L1xVEGF-A antibody candidate BNT327 and clinical progress in our focus programs and combination therapy approaches."

    The Company is advancing the development of its oncology pipeline. The strategic focus is on two pan-tumor programs: the immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, and mRNA cancer immunotherapy candidates. Promising clinical updates included initial data for the innovative combination of BNT327 with an antibody-drug conjugate (ADC) candidate.

    BioNTech shares appear to have halted their slide this year from over EUR 120 to EUR 80. H.C. Wainwright recently confirmed its "Buy" recommendation for the German biotech company's shares. However, the price target was reduced from USD 145 to USD 134.

    Cenit AG and other German and international small and mid-cap companies will present today, May 21, 2025, at the 15th IIF

    Agro Living Soils is a hot stock with huge potential. Given its potential and current market capitalization, investors can get in early. The D-Wave share has shown how quickly a tenfold increase is possible. It currently has a lot of momentum. However, the big tech giants will not let the first mover have the cake without a fight. BioNTech is expected to release further important data this year. If this is positive, the stock is currently anything but expensive.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on March 25th, 2026 | 09:35 CET

    Oil Volatility Shakes Markets – Life Sciences Stocks Back in Focus: Bayer, Vidac Pharma, Valneva, Novo Nordisk, and Pfizer

    • Biotechnology
    • Biotech
    • Pharma
    • LifeSciences

    The conflicts in the Middle East continue. With the first talks between the US and Iran, the stock markets made a lightning-fast upward adjustment. As a result, the German benchmark index DAX 40 gained a full 1,600 points within just 10 minutes at the start of the week. However, it was unable to hold that level, falling back to 22,600 points yesterday. The question now is whether the parties to the conflict can actually reach a viable solution. Completely unfazed by the broader market conditions, some news is making waves in the life sciences sector, driving price movements here and there. It is good to shift the focus away from daily market fluctuations and toward other profitable sectors. Here are a few ideas.

    Read

    Commented by Mario Hose on March 25th, 2026 | 07:00 CET

    The Mustard Revolution Is Here! How the Newcomer MustGrow Is Challenging Giants Bayer and K+S

    • mustard
    • Agritech
    • Agriculture
    • fertilizer

    We may already be, or soon find ourselves, at a dangerous crossroads in world history, where the mere availability of food becomes a decisive factor of power. While headlines are dominated by blocked shipping routes like the Strait of Hormuz and fertilizer shortages, a new alliance for supply security is forming on the stock market. Companies such as Bayer and K+S find themselves in a technical chart situation that raises only one key question: Is this a good entry opportunity? At the same time, the innovative pioneer MustGrow Biologics is preparing to disrupt the market from the ground up with its patented mustard-based technology. In this report, we analyze why the combination of established chemical power, strategic raw materials, fertilizers, and a biological revolution could stabilize your portfolio right now. Those who fail to take a closer look may miss the moment when the course for the coming years is set.

    Read

    Commented by Armin Schulz on March 20th, 2026 | 08:35 CET

    Act Now! Invest in cancer research with BioNTech, Vidac Pharma, and Pfizer and secure returns

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer

    Global healthcare spending is surging, and the oncology sector promises above-average returns. As the global population continues to age, the number of new cancer cases is expected to rise to over 30 million annually by 2040, intensifying competition among pharmaceutical companies for market share in this trillion-dollar industry. However, it is not yesterday's established drugs that offer the greatest profit potential, but rather radical technological shifts. While BioNTech is now deploying its billion-dollar mRNA platform against tumors, Vidac Pharma is pursuing an entirely novel approach aimed at starving cancer cells. At the same time, Pfizer is pushing aggressively into this field. We take a closer look at the current situation of these three companies.

    Read